February 1, 2009

5:00–7:00 pm

On-Site Registration

February 2, 2009

7:45 – 8:30 am

Registration & Continental Breakfast

8:30 – 8:35

Welcome & Opening Remarks - Howard Fillit, MD, Executive Director, Alzheimer's Drug Discovery Foundation

8:35 – 9:00

Plenary Talk: Overview of Drug Discovery for Neurodegenerative Disease - Howard Fillit, MD, Alzheimer's Drug Discovery Foundation - Click here to read session synopsis

I. Basics of Medicinal Chemistry - Click here to read session synopsis

Chair: D. Martin Watterson, PhD, Northwestern University

9:00 – 9:10

Session Overview – D. Martin Watterson, PhD 

9:10 – 9:30

Fundamentals of Medicinal Chemistry Refinement for CNS Compounds - Alan P. Kozikowski, PhD, University of Illinois at Chicago

9:30 – 9:40

Q&A

9:40 – 10:00

Rational Design and Medicinal Chemistry Refinement for Biosynthetic Enzymes - Richard B. Silverman, PhD, Northwestern University

10:00 – 10:10

Q&A

10:10 – 10:25

10:25 – 10:45

Ligand Development for Growth Factor Receptors - Frank M. Longo, MD, PhD, Stanford University

10:45 – 10:55

Q&A

10:55 – 11:15

Secretase Inhibitors: From Inhibitors towards CNS Drugs - Jordan Tang, PhD, Oklahoma Medical Research Foundation

11:15 – 11:25

Q&A

11:25 am – 11:45 pm

Hits to Leads to Drugs: What Makes a Chemical a Drug - Christopher Lipinski, PhD, Melior Discovery, Inc.  

11:45 – 11:55

Q&A

11:55 am – 1:00 pm

LUNCH

II. Hits & Leads: Early Phases of Drug Discovery - Click here to read session synopsis

Chair: Marcie Glicksman, PhD, Harvard NeuroDiscovery Center

1:00 – 1:10

Session Overview – Marcie Glicksman, PhD

1:10 – 1:30

Developing Relevant High-Throughput Assays for the Identification of Potential Drug Candidates - Marcie Glicksman, PhD, Harvard NeuroDiscovery Center

1:30 – 1:40

Q&A

1:40 – 2:00

Role of In Vitro Models in Drug Discovery for Neurodegenerative Disease - Linda Jo Van Eldik, PhD, Northwestern University

2:00 – 2:10

Q&A

2:10 – 2:30

In Vitro Toxicity Testing: What, Why & How - Karen L. Steinmetz, PhD, DABT, SRI International

2:30 – 2:40

Q&A

2:40 – 2:55

BREAK

III. Pre-Clinical Proof-of-Concept & Development - Click here to read session synopsis

Chair: Edward G. Spack, PhD, SRI International

2:55 – 3:05

Session Overview – Edward Spack, PhD

3:05 – 3:25

Characteristics of Compounds that Cross the Blood Brain Barrier - William A. Banks, MD, Saint Louis University School of Medicine

3:25 – 3:35

Q&A

3:35 – 3:55

Requirements for a Lead Compound to Become a Clinical Candidate - Nancy G. Wehner, PhD, Elan Pharmaceuticals

3:55 – 4:05

Q&A

4:05 – 4:25

Behavioral Testing in Neurodegenerative Disease - Daniela Brunner, PhD, PsychoGenics, Inc.

4:25 – 4:35

Q&A

4:35 – 4:55

The Basics of Pre-Clinical Development - Edward G. Spack, PhD, SRI International

4:55 – 5:05

Q&A

5:05 – 5:25

What Companies Look for in a Partner - Thomas Argentieri, PhD, Wyeth Pharmaceuticals

5:25 – 5:35

Q&A

5:35 – 5:45

Closing Remarks - Howard Fillit, MD, Alzheimer's Drug Discovery Foundation

5:45 – 7:00

NETWORKING RECEPTION

February 3, 2009

8:00 – 8:30 am

Continental Breakfast

8:30 – 8:40

Welcome & Opening Remarks - Suzana Petanceska, PhD, National Institute on Aging

IV. Issues in Technology Transfer: Interactions and Intellectual Property - Click here to read session synopsis

Chair: Kathleen A. Denis, PhD, Rockefeller University

8:40  – 8:45

Session Overview – Kathleen A. Denis, PhD

8:45 – 9:15

Working Effectively with Your TTO: Roles and Responsibilities - Kathleen A. Denis, PhD, Rockefeller University

9:15 – 9:25

Q&A

9:25 – 9:55

Intellectual Property 101: A Primer For Investigators - Colin G. Sandercock, Proskauer Rose LLP

9:55 – 10:05

Q&A

10:05 – 10:35

Creating Relationships with Industry: Consulting, Research, MTA's and Patent Licensing - Louis P. Berneman, PhD, Texelerate

10:35 – 10:45

Q&A

10:55 – 11:15

Should You Start a Biotechnology Company? - John S. Swartley, PhD, University of Pennsylvania

11:15 – 11: 25

Q&A

11:25 – 11:35

BREAK

V.  Ask the Experts: Drug Discovery for Neurodegenerative Disease - Click here to read session synopsis

Chair: Todd Sherer, PhD, Michael J. Fox Foundation for Parkinson's Research

11:35  – 11:40

Breakout Session Overview – Todd Sherer, PhD

11:40 am – 12:50 pm

Alzheimer’s Disease - Frank M. Longo, MD, PhD, Stanford University

Parkinson’s Disease - P. Jeffrey Conn, PhD, Vanderbilt University

Huntington’s Disease - Leticia Toledo-Sherman, PhD, CHDI Foundation

Amyotrophic Lateral Sclerosis - Jeffrey Rothstein, MD, PhD, Johns Hopkins University

Progressive Multiple Sclerosis - Fred D. Lublin, MD, Mount Sinai School of Medicine

12:50  – 1:50

LUNCH

VI. Resources and Services For Advancing Drug Discovery - Click here to read session synopsis

Chair: Lorenzo Refolo, PhD, National Institute on Neurological Disorders and Stroke

1:50 – 2:00

Session Overview - Lorenzo Refolo, National Institute on Neurological Disorders and Stroke

2:00 – 2:20

ADDME - Avoiding Drug Development Mistakes Early - Katya Tsaioun, PhD, Apredica

2:20 – 2:30

Q&A

2:30 – 2:50

Resources at the National Institute of Health - Suzana Petanceka, PhD, National Institute on Aging, and Lorenzo Refolo, PhD, National Institute of Neurological Disorders and Stroke

2:50 – 3:00

Q&A

3:00 – 3:20

Academic Models of Drug Discovery Services - D. Martin Watterson, PhD, Northwestern University

3:20 – 3:30

Q&A

3:30 – 4:00

Foundation Resources Panel

Chair: Howard Fillit, MD, ADDF

Panelists: Antony Horton, PhD, International Rett Syndrome Foundation;  Todd Sherer, PhD, Michael J. Fox Foundation for Parkinson's Research; Lucie Bruijn, PhD, ALS Association; and Cynthia Joyce, SMA Foundation.

4:00 – 4:10

Q&A

4:10 – 4:20

Closing Remarks - Howard Fillit, MD, Executive Director, ADDF